MultivisionDx

Tietoa

MultivisionDx develops AI-powered diagnostic tools leveraging spatial biology and computer vision to generate patient-specific tumor profiles for personalized cancer treatment. Spun out of the University of Helsinki with proof-of-concept research published in Cell, the company secured a EUR 1M pre-seed round in 2025 to commercialize its first-in-class composite biomarker for head-and-neck cancer and expand into additional solid tumor indications.